Home Healthcare Medical Devices Asia Pacific Cell Line Development Market to 2027

Asia Pacific Cell Line Development Market to 2027

Publisher: The Insight Partners
Publication Date: February, 2020
Healthcare / Medical Devices
Pages: 155
Delivery Format: PDF

Regional Analysis and Forecasts by Type (Primary Cell Line, Hybridomas, Continuous Cell Lines, and Recombinant Cell Line); By Product (Equipment and Media & Reagent); Application (Drug Discovery, Bioproduction and Tissue Engineering); and Geography

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

The Asia Pacific cell line development market is expected to reach US$ 2,813.78 Mn in 2027 from US$ 987.48 Mn in 2019. The market is estimated to grow with a CAGR of 14.0% from 2020-2027.

The growth of the cell line development market is primarily attributed to the increasing foreign direct investments in these countries, highly skilled, efficient, and a large number of human resources, streamlining government policies resulting in high expenditures for the biotechnology sector.

In the last few years, stem cell research became a significant field in the Asia Pacific medical sector, experiencing good development vision for the treatment of some challenging diseases. The government of the country organized various awareness programs for stem cell research. Moreover, the growing number of players operating across the country manufactures products for cell line development. The countries such as Australia, India, and South Korea are estimated to serve various growth opportunities due to the rising development in the biotechnology sector.

Moreover, the companies are performing various activities for the cell line development market, for instance, Selexis, Carestream Avacta, JSR Life Sciences. has done recent developments for products. Some of the recent developments are mentioned below.

Table 1. Recent Developments For Dental X-Ray in the Market
Month & Year Company Description
October, 2019 Teneobio Selexis SA and Teneobio, Inc. announced a commercial license agreement (CLA) for the development of Teneobio’s Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer.
June, 2019 Selexis Avacta Group plc and Selexis, a pioneering life sciences company and global leader in mammalian cell line generation technology, partnered to develop the Chinese hamster ovary (CHO) cell line that will be used to manufacture Avacta’s first Affimer clinical candidate for first-time-in-human clinical trials.
June, 2017 JSR Life Sciences JSR Life Sciences (JLS) announced to acquire Selexis SA, a pioneering life sciences company and global leader in mammalian (suspension-adapted CHO-K1) cell-line generation technologies. Selexis will be integrated within KBI Biopharma’s operations to create the most robust and fastest “Gene to GMP” service offering in the biopharmaceutical industry.

In 2018, the recombinant cell line segment held the most significant market share of the cell line development market, by type. This segment is also anticipated to dominate the market in 2027 owing to its popularity among manufacturers for the production of therapeutic recombinant proteins. The hybridomas segment is anticipated to witness growth at a significant rate during the forecast period.
The Japan cell line development market is dominated by intraoral media and reagent segment in 2019 with a considerable market share, by product. This segment is also predicted to dominate the market in 2027. Also, media and reagent segment is anticipated to witness growth at a significant rate during the forecast period, owing to the increasing research activities in biotechnology sector.

In 2019, the Bioproduction segment held a considerable market of the cell line development market, by the application. This segment is also predicted to dominate the market in 2027 owing to higher demand of biologics. However, the drug discovery segment is anticipated to witness growth at a significant rate during the forecast period.

Some of the major primary and secondary sources for cell line development included in the report are Chinese Academy of Sciences, Council of Scientific and Industrial Research, and others.

Reasons to buy this report:
• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the cell line development market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cell line development market market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Select Plan

1 User License $3,000

Site License License $4,000

Are you looking for a Consultant?

Email Us

Get a Quote

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$3,000

Asia Pacific Cell Line Development Market to 2027

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed